GILD

Gilead Sciences, Inc. · Healthcare · Drug Manufacturers - General
$134.43
-1.79 (-1.31%)
Mkt Cap: 166.90B
Key Metrics
MetricValue
P/E RatioN/A
EV/EBITDAN/A
ROEN/A
Gross MarginN/A
Revenue GrowthN/A
FCF Yield6.2%
Dividend YieldN/A
Market Cap166.90B
Volume16.64M
Recent News
Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
seekingalpha.com · 2026-05-29
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1--1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
gurufocus.com · 2026-05-27
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
businesswire.com · 2026-05-27
GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy
zacks.com · 2026-05-25
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference
marketbeat.com · 2026-05-24
US FDA approves Gilead's drug for deadly liver infection
reuters.com · 2026-05-22

Unlock the Full Deep Scan

9 AI agents analyze GILD across earnings, insider flow, macro conditions, corporate strategy, market microstructure, and price action.

Sign Up Free →